How Anti-Aging with Elysium Health will Reinvent Your Life

Leonard Pershing Guarente is an American biologist and an expert in the extension of the lifespan and a Novartis professor of Biology at the Massachusetts Institue of Technology. He earned his Ph.D. at Harvard University in 1978.

Guarente is a best known for his research on lifespan extension which research is ongoing at MIT’s Department of Biology which has developed the theoretical and practical protocol of the anti-aging research.

The MIT biology laboratory has focused on the theoretical bases underlying the aging process by studying the relationship between the molecular and genetic basis for aging. The research studied the molecular-genetic dichotomy using biological organisms.

The research then changed the model with an emphasis on mammals (mouse) and moved its investigation to human test subjects. Aging involves the study of the brain, and the mouse’s brain was used as the test subject.

The laboratory studied a chemical that is normally produced in the body, (NAD+). This chemical process generates energy. NAD+ is used as a dietary supplement which is portrayed as medicine. The amount of NAD+ is said to reduce as the body ages.

Elysium Health is a start-up dietary supplement company founded in 2014 by Leonard Guarente, Dan Alminana COO & Co-founder, and Eric Marcotulli CEO & Co-Founder. Guarantee used the results of the MIT Biology Department and developed what is called an anti-aging pill which contains NAD+ and named the pill Basis.

This pill does not receive FDA approval because Elysium does not represent a dietary supplement as medicine. Basis is advertised on the internet. The instruction in using the anti-aging pill is to follow a fasting protocol.</strong>

Thus, the anti-aging process includes the ingestion of NAD+ and fasting which Elysium states that this combination of pill and fasting promote the anti-aging process. The pill rejuvenates NAD+ to make up for its reduction as the body ages.

As of​ ​December​ ​2016,​ ​Elysium​ ​had​ ​raised​ ​$26.2​ ​million ​ ​from​ ​investors​. The investors included both​ ​​General​ ​Catalyst​ and ​Robert​ ​Nelson​ ​who is associated with ​ARCH​ ​Venture​ ​Partners.